Foundation Medicine teams up with Novartis for cancer diagnostics

The recently IPO'd Foundation Medicine ($FMI) has expanded its relationship with Novartis ($NVS), lending out its gene-profiling technology to help the drugmaker develop cancer treatments. Under the deal, Foundation will team up with Novartis to evaluate oncology candidates, develop biological targets and recruit patients for clinical trials, the company said, using the technology behind its FoundationOne diagnostic. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.